Indication
Follicular Variant Thyroid Gland Papillary Carcinoma
1 clinical trial
1 product
2 drugs
Clinical trial
Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted TherapyStatus: Active (not recruiting), Estimated PCD: 2024-10-31
Product
CabozantinibDrug
LurbinectedinDrug
T-VEC